SPOTLIGHT: Dendreon advances Provenge app

Dendreon says it has submitted two of the three sections required in its rolling application for the cancer drug Provenge. The chemistry, manufacturing and controls section of the application is scheduled to be filed later this year. Dendreon is seeking fast-track approval of Provenge for advanced prostate cancer patients whose cancer has spread. Report